Cancer immunotherapy trial registrations increase exponentially but chronic immunosuppressive glucocorticoid therapy may compromise outcomes

Ann Oncol. 2017 Jul 1;28(7):1678-1679. doi: 10.1093/annonc/mdx181.

Authors

C M Connell^{1

2}, S Raby¹, I Beh¹, T R Flint², E H Williams², D T Fearon^{2

3

4}, D I Jodrell^{1

2}, T Janowitz^{1

2}

Affiliations

¹ Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge.
² Cancer Research UK Cambridge Institute, University of Cambridge Li Ka Shing Centre, Cambridge, UK.
³ Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.
⁴ Weill Cornell Medical College, New York, USA.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Clinical Trials as Topic / statistics & numerical data*
Glucocorticoids / administration & dosage
Glucocorticoids / adverse effects*
Humans
Immunosuppressive Agents / administration & dosage
Immunosuppressive Agents / adverse effects*
Immunotherapy / adverse effects
Immunotherapy / methods
Immunotherapy / statistics & numerical data*
Neoplasms / drug therapy*
Neoplasms / immunology*
Registries
Treatment Outcome

Substances

Glucocorticoids
Immunosuppressive Agents

Grants and funding